Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietBG ControlIssue 682

Skipping Breakfast May Increase Risk of Type 2 Diabetes for Women

Glucose total AUC was greater in the no-breakfast group compared with the breakfast group....
Advertisement

During a press conference at ENDO 2013, Dr. Elizabeth A. Thomas from the University of Colorado School of Medicine, said skipping breakfast could have adverse cardiometabolic effects in obese women, including an increased risk for type 2 diabetes.

Thomas and colleagues conducted a randomized, crossover trial of 9 obese women aged 29.2 years (BMI 31.4 kg/m2) during 2 study days, roughly 1 month apart during the follicular phase of their menstrual cycle. They were randomly assigned to either breakfast containing 25% of daily energy intake or no breakfast at all. Their lunch contained 35% of their daily energy intake, Thomas said.

According to data, pre-lunch insulin levels did not differ between groups. However, glucose total AUC was greater in the no-breakfast group compared with the breakfast group (20,775 mg/dL vs. 18,126 mg/dL×180 minutes; P=.004).

Further, pre-lunch free fatty acids appeared higher among patients in the no-breakfast group compared with the breakfast group (705 mEq/L vs. 25,692 mEq/L×180 minutes; P=.0002).

Additional study data indicate the incremental AUC for free fatty acids was also greater among patients in the no-breakfast group compared with the breakfast group (–92980 vs. –26008 mEq/L ×180 minutes; P<.001). This suggests pre-lunch free fatty acids did not promote the increased AUC, according to Thomas.

Pre-lunch triglycerides were also lower in the no-breakfast group. However, the AUC did not vary between groups, suggesting that a pre-lunch triglyceride level drove the response, Thomas said.

"In obese women, skipping breakfast results in acute relative insulin resistance and elevated levels of free fatty acids," Thomas said. "It's possible that insulin resistance over time may predispose patients to further metabolic derangements and possibly progression to type 2 diabetes."

Practice 

  • Although the study was informative, other details need to be examined such as their other eating habits, which may be playing a role.

Presented at: The Endocrine Society Annual Meeting and Expo; June 15-18, 2013; San Francisco 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 21 June, 2013 and appeared in  DietBG ControlIssue 682

Past five issues: Diabetes Clinical Mastery Series Issue 225 | Issue 765 | Diabetes Clinical Mastery Series Issue 224 | Issue 764 | Diabetes Clinical Mastery Series Issue 223 |

2014 Most Popular Articles:

Significant Weight Loss and Drop in A1c with New Combo of Lorcaserin and Phentermine
Posted January 16, 2015
ADA Issues New Standards of Medical Care for Diabetes
Posted January 02, 2015
New Guidelines Recommend Off-Loading to Increase Likelihood of Diabetic Foot Ulcer Healing
Posted December 26, 2014
Handbook of Diabetes, 4th Ed., Excerpt #25: Specific Circumstances that Affect Diabetes Control
Posted January 04, 2015
Advancement in the Artificial Pancreas
Posted December 26, 2014
FDA Approves Weight-management Drug Saxenda
Posted December 26, 2014
Dr. Timothy Garvey on Qsymia and Other New Therapies for Weight Loss
Posted January 12, 2015
Type 2 Diabetes Risk Lower for Blood Type O
Posted December 26, 2014
Increased Mortality with Combining Sulfonylurea and Insulin
Posted December 26, 2014
Early Insulin Therapy Makes an Impact
Posted December 26, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will you prescribe inhaled insulin (Afrezza) when it becomes available this year?
CME/CE of the Week
Tracy Breen, MD

Category: General Diabetes
Credits: 1.0
Search Articles On Diabetes In Control